The evolving drug development landscape: From blockbusters to niche busters in the orphan drug space

Drug Development Research

Volumn 75, Issue 4, 2014, Pages 231-234

  Kakkar, Ashish Kumar ^a   Dahiya, Neha ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

COMPETITION; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; HUMAN; INVESTMENT; POPULATION GROUP; PROFIT; RARE DISEASE; REIMBURSEMENT; REVIEW; CLINICAL TRIAL (TOPIC); ECONOMICS; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; RARE DISEASES; TRENDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84902817437     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21176     Document Type: Review

References (24)

1. Boat TF, Field MJ. 2010. Rare diseases and orphan products. Washington, DC, National Academic Press
2. Braun MM, Farag-El-Massah S, Xu K, Coté TR. 2010. Emergence of orphan drugs in the United States: A quantitative assessment of the first 25 years. Nat Rev Drug Discov 9:519-522
3. Camurus. com. 2013. Camurus receives option-exercise milestone for octreotide FluidCrystal product CAM2029. Accessed on 12 Feb 2014. http://www. camurus. com/?DocumentID=6&Lang=sv &Show=%286%29&showsid= yes&main=News&newsID=43
4. Clissold DB. 1995. Prescription for the Orphan Drug Act: The impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Food Drug Law J 50:125-147
5. Côté A, Keating B. 2012. What is wrong with orphan drug policies? Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res 15:1185-1191
6. Dear JW, Lilitkarntakul P, Webb DJ. 2006. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol 62:264-271
7. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. 2007. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23:36-42
8. Dunoyer M. 2011. Accelerating access to treatments for rare diseases. Nat Rev Drug Discov 10:475-476
9. EC. europa. eu. 2014. Policy-European Commission. [online]. Accessed on 3 Jan 2014. http://ec. europa. eu/health/rare-diseases/policy/indexen. htm
10. EvaluatePharma. 2013. EvaluatePharma Orphan Drug Report 2013. Accessed on 2 May 2013. http://www. evaluategroup. com/public/Reports/EvaluatePharma- Orphan-Drug-Report-2013. aspx
11. FDA 2014a. Developing Products for Rare Diseases & Conditions. Accessed on 23 Jan 2014. http://www. fda. gov/forindustry/ DevelopingProductsforrareDiseasesConditions/default. htm
12. FDA. 2014b. Orphan Drug Act. Accessed on 5 Jan 2014. http://www. fda. gov/regulatoryinformation/legislation/federalfood drugandcosmeticactfdcact/ significantamendmentstothefdcact/orphandrugact/default. htm
13. FDA. 2014c. Orphan Products: Hope for People With Rare Diseases. Accessed on 5 Jan 2014. http://www. fda. gov/Drugs/Resources ForYou/Consumers/ucm143563. htm
14. FDA. 2014d. Search Orphan Drug Designations and Approvals. [online] Accessed on 15 Feb 2014. http://www. accessdata. fda. gov/scripts/opdlisting/ oopd/index. cfm
15. Haffner ME, Whitley J, Moses M. 2002. Two decades of orphan product development. Nat Rev Drug Discov 1:821-825
16. Heemstra HE, van Weely S, Büller HA, Leufkens HGM, de Vrueh RLA. 2009. Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today 14:1166-1173
17. Hyde R, Dobrovolny D. 2010. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Amer Health Drug Benefit 3:15-23
18. Medical Billing & Coding. 2012. The 11 Most Expensive Medicines in America. Accessed on 6 Feb 2012. http://www. medicalbillingandcoding. org/blog/the-11-most-expensive-medicines-in-america/
19. Meekings KN, Williams CSM, Arrowsmith JE. 2012. Orphan drug development: An economically viable strategy for biopharma R&D. Drug Discov Today 17:660-664
20. Phillips MI. 2013. Big Pharma's new model in orphan drugs and rare diseases. Exp Opin Orphan Drugs 1:1-3
21. Rockoff JD, Winslow R. 2013. New Medicines Emerge, but Few Blockbusters. Wall Street Journal. Accessed on 15 Dec 2013. http://online. wsj. com/news/articles/SB1000142405270230428100 4579222362098933226
22. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. 2008. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 3:33
23. Simoens S. 2011. Pricing and reimbursement of orphan drugs: The need for more transparency. Orphanet J Rare Dis 6:42
24. Thomson Reuters. 2012. The Economic Power of Orphan Drugs. Accessed on 15 Jan 2014. http://thomsonreuters. com/products/ipscience/04-013/1001450. pdf.